Brain Cancer | Specialty

What is Glioblastoma?

December 21st 2016

Dr. Reardon on the Need for a New Standard of Care in GBM

December 1st 2016

David A. Reardon, MD, clinical director at the Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the need for a new standard of care in the treatment landscape of glioblastoma multiforme.

Tumor-Treating Fields Make Significant Impact in GBM

December 1st 2016

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma

November 30th 2016

The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.

Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer

November 22nd 2016

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma

November 20th 2016

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

November 20th 2016

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

Durvalumab Shows Durable Activity in Recurrent GBM

November 20th 2016

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

AG-120 Shows Early Efficacy in IDH1-Mutant Glioma

November 20th 2016

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.

Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer

November 19th 2016

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Optune Survival Benefit in GBM Sustained With Long-Term Data

November 19th 2016

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

November 19th 2016

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

November 19th 2016

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

November 19th 2016

Checkpoint Inhibitors Show Promise in Glioblastoma

November 19th 2016

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study

November 18th 2016

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM

November 18th 2016

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer

November 18th 2016

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

November 18th 2016

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

November 10th 2016

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.